Metabolomics Analysis of Acute Kidney Injury and Delirium After Cardiac Surgery (NCT06508593) | Clinical Trial Compass
CompletedNot Applicable
Metabolomics Analysis of Acute Kidney Injury and Delirium After Cardiac Surgery
China120 participantsStarted 2024-07-20
Plain-language summary
Clinical evidence suggests that renal injury leads to changes in the structure of the cerebral cortex in patients, suggesting the existence of the renal brain axis. Therefore, some scholars have proposed that AKI may be an important cause of secondary injuries such as delirium. Approximately 60% of AKI patients in clinical practice experience delirium.Although the underlying mechanism associated with acute renal injury and delirium is still unclear, it has been recognized that it increases incidence rate and mortality, prolongs hospital stay, and accelerates long-term cognitive decline. The investigators assume that the serum metabolic profiles of patients with delirium and AKI after cardiac surgery, with delirium only, with AKI only, and without delirium or AKI after surgery can be compared separately to explore the mechanisms of complications and the interaction mechanisms between organ damage after extracorporeal circulation cardiac surgery, and to identify metabolic markers specific to complications, identify patients with increased susceptibility, and provide reference for early diagnosis of complications and basis for early intervention.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. 18 years old and above
. Patients undergone elective cardiac surgery
. History of serum creatinine test within 7 days before surgery
. Provide venous blood samples
. Voluntarily participate and sign an informed consent form
Exclusion criteria
. Patients treated with chronic peritoneum or hemodialysis, prior kidney transplantation, preoperative serum creatinine level\>4.5mg/dL (400 μ mol/L) or end-stage renal disease (defined as glomerular filtration rate\<15ml · min-1 · 1.73m-2)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Small molecule metabolites specific to complications after extracorporeal circulation cardiac surgery
. Other related diseases that have been previously confirmed to have cognitive impairment, or records of using drugs targeting cognitive impairment during the onset period
. Individuals with severe speech, visual, hearing, or mental impairments that affect cognitive scale assessment
. Individuals with a history of brain tumors, traumatic brain injury, brain parasitic diseases, and other diseases that may cause cognitive impairment
. Individuals with a history of alcohol and drug addiction